bioTheranosticsâ€™ Breast Cancer IndexSM Molecular Test Identifies Risk for Early and Late Breast Cancer Recurrence, Lancet Oncology Study Finds
bioTheranostics Is Now an In-Network Provider with Highmark Health Services for Its
CancerTYPE IDÂ® Molecular Test for Metastatic Cancer
Studies Further Demonstrate Clinical Utility & Cost-Effectiveness of bioTheranosticsâ€™ CancerTYPE IDÂ® Molecular Test in Metastatic Cancer
Medical Laboratory Observer:
Under Richard Dingâ€™s direction, bioTheranostics focuses on biomarkers to aid in cancer treatment
Journal of Clinical Oncology:
Molecular Gene Expression Profiling to Predict the Tissue of Origin and Direct Site-Specific Therapy in Patients With Carcinoma of Unknown Primary Site: A Prospective Trial of the Sarah Cannon Research Institute
bioTheranostics develops and provides innovative oncology tests to support targeted disease management.
bioT3 is a suite of genomic-based tests that provide diagnostic and therapeutic information for metastatic cancer patients at any stage across the continuum of care.
Breast Cancer IndexSM predicts the risk of late
(post 5 years) recurrence and the likelihood of benefit from extended endocrine therapy
Learn More >